O. Lortholary, J. Gangneux, and K. Sitbon, Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005???2007), Clinical Microbiology and Infection, vol.17, issue.12, pp.1882-1891, 2005.
DOI : 10.1111/j.1469-0691.2011.03548.x

URL : https://hal.archives-ouvertes.fr/hal-00680990

A. Pascual, T. Calandra, and S. Bolay, Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes, Clinical Infectious Diseases, vol.46, issue.2, pp.201-212, 2008.
DOI : 10.1086/524669

M. Dolton, J. Ray, and S. Chen, Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring, Antimicrobial Agents and Chemotherapy, vol.56, issue.9, pp.4793-4802, 2012.
DOI : 10.1128/AAC.00626-12

S. Miyakis, S. Van-hal, and J. Ray, Voriconazole concentrations and outcome of invasive fungal infections, Clinical Microbiology and Infection, vol.16, issue.7, pp.927-960, 2010.
DOI : 10.1111/j.1469-0691.2009.02990.x

M. Hoenigl, W. Duettmann, and R. Raggam, Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological Malignancies, Antimicrobial Agents and Chemotherapy, vol.57, issue.7, pp.3262-3269, 2013.
DOI : 10.1128/AAC.00251-13

Z. Racil, J. Winterova, and M. Kouba, Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience, Mycoses, vol.55, issue.Suppl. 1, pp.483-92, 2012.
DOI : 10.1111/j.1439-0507.2012.02186.x

S. Trifilio, R. Ortiz, and G. Pennick, Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients, Bone Marrow Transplantation, vol.35, issue.5, pp.509-522, 2005.
DOI : 10.1038/sj.bmt.1704828

S. Miyakis, S. Van-hal, and C. Solvag, Clinician Ordering Practices for Voriconazole Therapeutic Drug Monitoring: Experiences of a Referral Laboratory, Therapeutic Drug Monitoring, vol.32, issue.5, pp.661-665, 2010.
DOI : 10.1097/FTD.0b013e3181ea3de6

S. Trifilio, P. Yarnold, and M. Scheetz, Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation, Antimicrobial Agents and Chemotherapy, vol.53, issue.5, pp.1793-1799, 2009.
DOI : 10.1128/AAC.01316-08

Y. Nivoix, D. Levêque, and R. Herbrecht, The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole Antifungals, Clinical Pharmacokinetics, vol.9, issue.4, pp.779-92, 2008.
DOI : 10.2165/0003088-200847120-00003

D. Mitsani, M. Nguyen, and R. Shields, Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity, Antimicrobial Agents and Chemotherapy, vol.56, issue.5, pp.2371-2378, 2012.
DOI : 10.1128/AAC.05219-11

W. Hope, Population Pharmacokinetics of Voriconazole in Adults, Antimicrobial Agents and Chemotherapy, vol.56, issue.1, pp.526-557, 2012.
DOI : 10.1128/AAC.00702-11

M. Dolton, G. Mikus, and J. Weiss, Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing, Journal of Antimicrobial Chemotherapy, vol.69, issue.6, pp.1633-1674, 2014.
DOI : 10.1093/jac/dku031

W. Park, N. Kim, and K. Kim, The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial, Clinical Infectious Diseases, vol.55, issue.8, pp.1080-1087, 2012.
DOI : 10.1093/cid/cis599

D. Andes and A. Lepak, Editorial Commentary: Antifungal Therapeutic Drug Monitoring Progress: Getting It Right the First Time, Clinical Infectious Diseases, vol.55, issue.3, pp.391-394, 2012.
DOI : 10.1093/cid/cis446

R. Hyland, B. Jones, D. Smith, A. Hassan, J. Burhenne et al., Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children, Drug Metab Dispos Ther Drug Monit J Pediatr Hematol Oncol, vol.31, issue.35, pp.540-547, 2003.

T. Wang, S. Chen, and J. Sun, Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections, Journal of Antimicrobial Chemotherapy, vol.69, issue.2, pp.463-70, 2014.
DOI : 10.1093/jac/dkt369

M. Berge, R. Guillemain, and D. Trégouet, Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients, European Journal of Clinical Pharmacology, vol.34, issue.3, pp.253-60, 2011.
DOI : 10.1007/s00228-010-0914-2

D. Pauw, B. Walsh, T. Donnelly, and J. , Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group, Clinical Infectious Diseases, vol.46, issue.12, pp.1813-1834, 2008.
DOI : 10.1086/588660

J. Jourdil, J. Tonini, and F. Stanke-labesque, Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional highperformance liquid chromatography-tandem mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci, vol.919920, pp.1-9, 2013.

J. Mega, S. Close, and S. Wiviott, Cytochrome P-450 Polymorphisms and Response to Clopidogrel, New England Journal of Medicine, vol.360, issue.4, pp.354-62, 2009.
DOI : 10.1056/NEJMoa0809171

URL : http://dx.doi.org/10.1016/j.jvs.2009.02.023

S. Rodriguez, T. Gaunt, and I. Day, Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies, American Journal of Epidemiology, vol.169, issue.4, pp.505-519, 2009.
DOI : 10.1093/aje/kwn359

M. Kollef, S. Micek, and N. Hampton, Septic Shock Attributed to Candida Infection: Importance of Empiric Therapy and Source Control, Clinical Infectious Diseases, vol.54, issue.12, pp.1739-1785, 2012.
DOI : 10.1093/cid/cis305

M. Morrell, V. Fraser, and M. Kollef, Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality, Antimicrobial Agents and Chemotherapy, vol.49, issue.9, pp.3640-3645, 2005.
DOI : 10.1128/AAC.49.9.3640-3645.2005

L. Elens, A. Capron, and R. Van-schaik, Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal Transplantation, Therapeutic Drug Monitoring, vol.35, pp.608-624, 2013.
DOI : 10.1097/FTD.0b013e318296045b

M. Neely, T. Rushing, and A. Kovacs, Voriconazole Pharmacokinetics and Pharmacodynamics in Children, Therapeutic Drug Monitoring of Voriconazole, pp.27-36, 2010.
DOI : 10.1086/648679

S. Trifilio, G. Pennick, and J. Pi, Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients, Cancer, vol.44, issue.8, pp.1532-1537, 2007.
DOI : 10.1002/cncr.22568

N. Boyd, C. Zoellner, and M. Swancutt, Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections, Antimicrobial Agents and Chemotherapy, vol.56, issue.11
DOI : 10.1128/AAC.00700-12

X. Li, T. Andersson, and M. Ahlström, COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES, Drug Metabolism and Disposition, vol.32, issue.8, pp.821-828, 2004.
DOI : 10.1124/dmd.32.8.821

H. Johnson, K. Han, and B. Capitano, Voriconazole Pharmacokinetics in Liver Transplant Recipients, Antimicrobial Agents and Chemotherapy, vol.54, issue.2, pp.852-861, 2010.
DOI : 10.1128/AAC.00429-09

H. Chu, R. Jain, and H. Xie, Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections, BMC Infect Dis Clin Infect Dis, vol.13, issue.55, pp.381-90, 2012.

J. Tonini, A. Thiébaut, and J. Jourdil, Therapeutic Drug Monitoring of Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Patients Who Develop Gastrointestinal Graft-versus-Host Disease, Antimicrobial Agents and Chemotherapy, vol.56, issue.10, pp.5247-52, 2012.
DOI : 10.1128/AAC.00815-12

URL : https://hal.archives-ouvertes.fr/hal-00849695

J. Mega, S. Close, and S. Wiviott, Cytochrome P-450 Polymorphisms and Response to Clopidogrel, New England Journal of Medicine, vol.360, issue.4, pp.354-62, 2009.
DOI : 10.1056/NEJMoa0809171

R. Bibliographiques-1, R. Herbrecht, D. Denning, and T. Patterson, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, N Engl J Med, vol.347, pp.408-423, 2002.

O. Lortholary, J. Gangneux, and K. Sitbon, Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005???2007), Clinical Microbiology and Infection, vol.17, issue.12, pp.1882-1891, 2005.
DOI : 10.1111/j.1469-0691.2011.03548.x

URL : https://hal.archives-ouvertes.fr/hal-00680990

A. Pascual, T. Calandra, and S. Bolay, Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes, Clinical Infectious Diseases, vol.46, issue.2, pp.201-212, 2008.
DOI : 10.1086/524669

M. Dolton, J. Ray, and S. Chen, Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring, Antimicrobial Agents and Chemotherapy, vol.56, issue.9, pp.4793-4802, 2012.
DOI : 10.1128/AAC.00626-12

M. Hoenigl, W. Duettmann, and R. Raggam, Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological Malignancies, Antimicrobial Agents and Chemotherapy, vol.57, issue.7, pp.3262-3269, 2013.
DOI : 10.1128/AAC.00251-13

Z. Racil, J. Winterova, and M. Kouba, Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience, Mycoses, vol.55, issue.Suppl. 1, pp.483-92, 2012.
DOI : 10.1111/j.1439-0507.2012.02186.x

S. Trifilio, R. Ortiz, and G. Pennick, Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients, Bone Marrow Transplantation, vol.35, issue.5, pp.509-522, 2005.
DOI : 10.1038/sj.bmt.1704828

W. Park, N. Kim, and K. Kim, The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial, Clinical Infectious Diseases, vol.55, issue.8, pp.1080-1087, 2012.
DOI : 10.1093/cid/cis599

R. Hyland, B. Jones, D. Smith, A. Narita, H. Muramatsu et al., Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring, Drug Metab Dispos J Pediatr Hematol Oncol Ther Drug Monit, vol.31, issue.33, pp.540-547, 2003.

D. Wang, Y. Guo, and S. Wrighton, Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, The Pharmacogenomics Journal, vol.34, issue.4, pp.274-86, 2011.
DOI : 10.2217/pgs.09.42

P. Kuehl, J. Zhang, and Y. Lin, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nature Genetics, vol.27, issue.4, pp.383-91, 2001.
DOI : 10.1038/86882

N. Boyd, C. Zoellner, and M. Swancutt, Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections, Antimicrobial Agents and Chemotherapy, vol.56, issue.11
DOI : 10.1128/AAC.00700-12

D. Mitsani, M. Nguyen, and R. Shields, Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity, Antimicrobial Agents and Chemotherapy, vol.56, issue.5, pp.2371-2378, 2012.
DOI : 10.1128/AAC.05219-11

S. Miyakis, S. Van-hal, and J. Ray, Voriconazole concentrations and outcome of invasive fungal infections, Clinical Microbiology and Infection, vol.16, issue.7, pp.927-960, 2010.
DOI : 10.1111/j.1469-0691.2009.02990.x

M. Neely, T. Rushing, and A. Kovacs, Voriconazole Pharmacokinetics and Pharmacodynamics in Children, Clinical Infectious Diseases, vol.50, issue.1, pp.27-36, 2010.
DOI : 10.1086/648679

S. Trifilio, P. Yarnold, and M. Scheetz, Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation, Antimicrobial Agents and Chemotherapy, vol.53, issue.5, pp.1793-1799, 2009.
DOI : 10.1128/AAC.01316-08

J. Jourdil, J. Tonini, and F. Stanke-labesque, Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional highperformance liquid chromatography-tandem mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci, vol.919920, pp.1-9, 2013.

J. Mega, S. Close, and S. Wiviott, Cytochrome P-450 Polymorphisms and Response to Clopidogrel, New England Journal of Medicine, vol.360, issue.4, pp.354-62, 2009.
DOI : 10.1056/NEJMoa0809171

M. Kollef, S. Micek, and N. Hampton, Septic Shock Attributed to Candida Infection: Importance of Empiric Therapy and Source Control, Clinical Infectious Diseases, vol.54, issue.12, pp.1739-1785, 2012.
DOI : 10.1093/cid/cis305

M. Morrell, V. Fraser, and M. Kollef, Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality, Antimicrobial Agents and Chemotherapy, vol.49, issue.9, pp.3640-3645, 2005.
DOI : 10.1128/AAC.49.9.3640-3645.2005

G. Weiss and J. , Are We Ready for Clinical Implementation of Pharmacogenomics? Pharmacotherapy 2014, sous presse. 26 Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing, Therapeutic Drug Monitoring of Voriconazole, pp.1633-1674, 2014.

X. Li, T. Andersson, and M. Ahlström, COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES, Drug Metabolism and Disposition, vol.32, issue.8, pp.821-828, 2004.
DOI : 10.1124/dmd.32.8.821

H. Johnson, K. Han, and B. Capitano, Voriconazole Pharmacokinetics in Liver Transplant Recipients, Antimicrobial Agents and Chemotherapy, vol.54, issue.2, pp.852-861, 2010.
DOI : 10.1128/AAC.00429-09

H. Chu, R. Jain, and H. Xie, Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events, BMC Infectious Diseases, vol.3, issue.11, p.105, 2013.
DOI : 10.1186/1471-2288-3-28